http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yuri Jeong,Jeong Geun Oh,Jeong Ku Kang,Sun Rock Moon,Kang Kyoo Lee 대한방사선종양학회 2020 Radiation Oncology Journal Vol.38 No.1
Purpose: We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer. Materials and Methods: Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD98%, DD2% and DDmean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm. Results: The GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DDmean (%) for rectum and bladder. Conclusions: The 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer.
Clinical Implication of Dacryoendoscopy in the Patients with Tearing: A Systematic Review
Yuri Kim(Yuri Kim),Jeong Yoon Park(Jeong Yoon Park),Helen Lew(Helen Lew) 대한안과학회 2023 Korean Journal of Ophthalmology Vol.37 No.3
Purpose: A systematic review of the literature on diagnostic and therapeutic indications, techniques, and complications of dacryoendoscopy (DE) was performed. Methods: The authors performed a PubMed search of articles published in English on DE. Data were collected and classified according to the categories of the disease. The clinical outcomes and limitations were particularly analyzed. Results: The lacrimal drainage system from the canaliculus to the inferior meatus could be examined based on the specific anatomical features by DE. The canalicular mucosa is smooth and brightly colored, the lacrimal sac shows covering mucosa with good vascularization and the nasolacrimal duct is lined with bright tubular mucosal folds. DE allows direct visualization of the detailed internal condition of the lacrimal disorders, to directly diagnose the site of obstruction with accuracy and address the causes and recanalize the lacrimal drainage system using assisted micro lacrimal surgical instruments in the tearing patients. Conclusions: Better visualization of the lacrimal canal with DE improves the understanding of physiology and precise identification of the obstructing lesions, both of which are the key to a comprehensive management for the tearing patients.
( Yuri Cho ),( Jeong Hoon Lee ),( Dong Hyeon Lee ),( Min Jong Lee ),( Jeong Ju Yoo ),( Won Mook Choi ),( Young Youn Cho ),( Yun Bin Lee ),( Eun Ju Cho ),( Su Jong Yu ),( Nam Joon Yi ),( Kwang Woong Le 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background/aims: Some patients with hepatocellular carcinoma (HCC) beyond the Milan criteria (MC) have favorable tumor biology, and that these patients would have low risk of tumor recurrence after living donor liver transplantation (LDLT). This study was designed to develop a model of tumor recurrence after LDLT for HCC beyond the MC, so as to select the best candidates for LDLT in HCC beyond the MC. Methods: Consecutive patients who had undergone LDLT beyond the MC at Seoul National University Hospital between September 2001 and January 2013 were analyzed. Demographic, clinical, and tumor characteristics were evaluated and a model to predict recurrence after LDLT (MoRAL score) was created. Results: A total of 104 patients were included. The median follow-up was 52.7 (range, 1.6-157.5) months. Their 5-year overall survival and cumulative recurrence rates were 70.4% and 41.8%, respectively. In multivariate analysis, independent pretransplant risk factors for HCC recurrence were serum AFP (OR=1.003, P=0.013) and PIVKA-II (OR=1.001, P=0.050) levels. AFP reflected maximal tumor size and PIVKA-II reflected tumor number and type (nodular or diffuse/infiltrative) (all P<0.001). Using Cox proportional hazards model, MoRAL score ( )was derived (median, 108.3; range 33.7-3928.3). The concordance statistic of MoRAL (0.836) was superior to CLIP score (0.772), TNM stage (0.600), JIS stage (0.601) and T classification (0.626). The tumor recurrence after LDLT was significantly related to mortality (OR=21.6, P<0.001). Conclusions: A new model to predict tumor recurrence of HCC patients beyond the MC after LDLT based on objective parameters provides refined prognostication (Figure 1). External validation is warranted.
A Novel Synthesis of N-Sulfonylformamidines from N-Sulfonylsulfonamides
Jeong, Yuri,Ban, Jaeyoung,Lim, Minkyung,Rhee, Hakjune Georg Thieme Verlag 2018 Synthesis Vol.50 No.9
<P> N-Sulfonylformamidines were synthesized from N-sulfonylsulfonamides by reacting with p-toluenesulfonyl chloride (TsCl) and N,N -disubstituted formamides. In this reaction, it was expected that mixing TsCl with the N,N-disubstituted formamide would generate an iminium salt (Vilsmeier reagent). The reaction avoids the use of metal catalysts and hazardous reagents, and the desired N-sulfonylformamidines were obtained in 60% to quantitative yields.</P>
( Yuri Cho ),( Jeong Hoon Lee ),( Dong Hyeon Lee ),( Minjong Lee ),( Jeong Ju Yoo ),( Won Mook Choi ),( Young Youn Cho ),( Yun Bin Lee ),( Su Jong Yu ),( Yoon Jun Kim ),( Jung Hwan Yoon ),( Chung Yong 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background/aims: Entecavir (ETV) has an excellent efficacy in nucleos(t)ide analogue (NA)-naive chronic hepatitis B (CHB) patients, but data on the efficacy in patients who were exposed to lamivudine (LAM) but never developed LAM-resistance (LAM-R) are limited. In this study, we aimed to evaluate whether the probability of developing genotypic resistance to ETV in currently or previously LAM-exposed patients with/ without LAM-R is comparable to that in antiviral-naive patients. Methods: This study included 500 consecutive patients with CHB who started ETV monotherapy at a single tertiary hospital (Seoul, Korea) from 2007 to 2012. The patients were divided into three groups: NA-naive patients (group 1, n=142), patients who were ever exposed to LAM, but never developed LAM-R (group 2, n=233), and patients with LAM-R when starting ETV (group 3, n=125). The probabilities of developing ETV-resistance (ETV-R) were determined and compared by multivariate analysis. Results: Overall median treatment duration was 194.9 weeks (range, 41.4-337.0 weeks). The probabilities of virologic breakthrough were increased not only in group 3 (32.4%) but also in group 2 (10.3%), compared to group 1 (3.2%) (both P≤0.001). Genotypic ETV-R was more frequently developed in group 2 (odds ratio=17.3, P=0.006) as well as group 3 (odds ratio=57.4, P<0.001) than in group 1: the probabilities of developing ETVR in group 1, 2, and 3 were 0%, 33.7% and 49.8%, respectively, at week 192. Conclusions: This study indicates that ETV-R was developed more frequently in LAM-exposed patients, even though they never developed LAM-R, as compared to NA-naive patients. Therefore, LAM-exposed CHB patients, regardless of LAM-R, should be monitored more cautiously for the development of ETV-R during ETV monotherapy and further prospective studies on proper therapies in LAM-exposed patients are war ranted.
( Yuri Cho ),( Dong Hyeon Lee ),( Kwang Hyun Chung ),( Jeong Hoon Lee ),( Eun Ju Cho ),( Eun Sun Jang ),( Min Sun Kwak ),( Su Jong Yu ),( Jin Wook Kim ),( Sook Hyang Jeong ),( Jung Hwan Yoon ),( Hyo S 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background: The efficacy of adefovir (ADV) plus entecavir (ETV) combination in patients with chronic hepatitis B (CHB) who developed multidrug resistance had not been fully evaluated. We aimed to evaluate the efficacy of ADV plus ETV as compared to that of LAM plus ADV in patients with antiviral resistance to both LAM and ADV. Methods: 27 patients were treated with a combination of ADV plus ETV and 63 patients were treated with a combination of LAM plus ADV. The virological and biochemical parameters were compared between the two groups. Results: Treatment with a combination of ADV plus ETV produced a significantly superior in virological response compared to that in the LAM plus ADV group during 12 months of therapy. At 12 months, the HBV DNA declined more in the ADV plus ETV than in the LAM plus ADV (-4.52 ± 1.956 vs. -2.65 ± 1.723 log10IU/mL; p = 0.001). The rate of a complete response at 12 months was greater in the ADV plus ETV than that in the LAM plus ADV (73.68% vs. 31.48%, p = 0.005). Conclusions: In patients with CHB resistant to both LAM and ADV, the response to ADV plus ETV was significantly superior compared to that of the LAM plus ADV for suppressing HBV DNA through 12 months. The result indicates that ADV plus ETV rather than LAM plus ADV might be used as a bridging therapy in patients with CHB resistant to both LAM and ADV, especially in areas where tenofovir is not available.